News Archive
A Year in Review – Reflecting on 2025
As we look back on 2025, we are excited to share some of the year’s highlights with you! Read more.
Prenatal Samples and Methylation Patterns
Several studies highlight the challenges inherent to using prenatal samples for methylation analysis. Therefore, we do not recommend using MS-MLPA probemixes on prenatal samples. Read more.
Expanding Access to Newborn Screening with MRC Holland's Melt Assay for Spinal Muscular Atrophy
MRC Holland's Melt Assay for SMA screening in newborns addresses the need for easy‑to‑adopt first‑tier screening technologies as more countries move toward implementing national newborn screening programs. Read more.
The Status of DNA‑Based Technologies in Newborn Screening
A recent publication by MRC Holland researchers contributes valuable insights into the evolving field of newborn screening (NBS). Read more.
Changes to Our Product Packaging
Our product packaging will receive updates which simplify processing and pave the way for future innovations – there are no changes to the product contents.
NXtec D007 Acute Lymphoblastic Leukemia as a Valuable Tool in pALL Testing
D007 Acute Lymphoblastic Leukemia was recognized as a valuable tool for enhanced molecular testing of pediatric acute lympoblastic leukemia (pALL) in a recent research article. Read more.
New Product: NXtec D024 KaryoProfiler — High-Throughput, High-Resolution Alternative to Traditional Karyotyping
We have launched NXtec D024 KaryoProfiler, our newest digitalMLPA™ assay designed for comprehensive molecular karyotyping across a wide range of applications. Read more.
New Product Launch: NXtec D002 Hereditary Cancer Panel 2 for Broad Hereditary Cancer Analysis
Introducing NXtec Hereditary Cancer Panel 2 – a broad panel for the detection of CNVs in cancer-associated genes and the presence of selected variants.
Improved – P242 Pancreatitis – Now Featuring Mutation-Specific Probes for SPINK1 and PRSS1
P242 Pancreatitis just received a major update, with the recently released D1 version featuring nine new target probes and three new mutation-specific probes, as well as three replaced target probes and eight replaced reference probes. The updated probe content facilitates enhanced detection of HP-related genetic alterations and improves assay robustness.
MRC Holland Visiting Scientist to Present on Newborn Screening at International Conferences
Terence Diane Fabella, a PhD candidate and MRC Holland researcher, will present her work on the development of digitalMLPA assays for newborn screening at three international conferences later this year.